Grail, Inc.(US:GRAL)2026-02-19 23:02Financial Data and Key Metrics Changes - Fourth quarter revenue was $43.6 million, an increase of $5.3 million, or 14%, compared to Q4 2024 [20] - Full year total revenue was $147.2 million, up 17% from 2024, with screening revenue of $138.6 million, up 28% [20][21] - Net loss for Q4 2025 was $99.2 million, a 2% increase compared to Q4 2024, while full year net loss improved by 80% to $408.4 million [22] - Non-GAAP adjusted gross profit for Q4 2025 was $23.1 million, a 29% increase compared to Q4 2024 [23] - Adjusted EBITDA for Q4 2025 was -$71.8 million, an improvement of 15% compared to Q4 2024 [24] Business Line Data and Key Metrics Changes - U.S. Galleri tests volume grew 36% to over 185,000 tests in 2025, with revenue growth of 26% [8] - Development services revenue decreased by 49% to $8.6 million in 2025 [21] Market Data and Key Metrics Changes - The prescriber base for Galleri increased by 30% to approximately 17,000 providers [8] - The company is focused on expanding awareness of multi-cancer early detection and anticipates growing conviction in Galleri among patients, providers, and employers [9] Company Strategy and Development Direction - The company plans to expand its field sales and medical team to drive commercial momentum [7] - The PMA submission to the FDA for Galleri marks a critical step in making the test available to more people [9] - The company aims to leverage strong results from clinical trials to expand partnerships and access to Galleri [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for Galleri to bend the cancer mortality curve at a population scale [16] - The company reiterated guidance for Galleri sales growth of 22%-32% and cash burn for 2026 to be no more than $300 million [26] - The cash runway extends into 2030, positioning the company well for future growth [26] Other Important Information - The NHS-Galleri trial showed a fourfold increase in cancer detection rates and a significant reduction in stage 4 cancer diagnoses [5][12] - The company plans to present full data from the NHS-Galleri and PATHFINDER 2 studies in mid-2026 [27][90] Q&A Session Summary Question: Will the FDA approval decision be impacted by missing the stage shift endpoint? - Management confirmed that the FDA will focus on clinical performance and safety, and there is no obvious correlation between the NHS-Galleri study results and the FDA's view on the test [31] Question: How does the NHS-Galleri trial impact the strategy to expand Galleri internationally? - Management believes the strong data from the NHS-Galleri trial will be compelling for discussions with other countries [36] Question: What is the probability of FDA approval unchanged as a result of the NHS Galleri readout? - Management indicated that the probability remains unchanged, focusing on clinical performance and safety in their submission [45][50] Question: What are the next steps regarding the NHS and the multi-cancer early detection tests? - Management has ongoing conversations with the NHS and anticipates that they will want to see full results before engaging in meaningful discussions [62] Question: How will Medicare evaluate the NHS trial data for coverage? - Management believes they will provide a robust package of data to Medicare, including substantial stage 4 reduction and overall clinical performance [67]